Last reviewed · How we verify
phosphate and betamethasone acetate, 2 mL.
Betamethasone acetate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production.
Betamethasone acetate is a corticosteroid that suppresses inflammatory and immune responses by binding to glucocorticoid receptors and inhibiting pro-inflammatory cytokine production. Used for Intra-articular injection for inflammatory arthritis and joint inflammation, Soft-tissue injection for bursitis, tendinitis, and localized inflammatory conditions, Dermatologic inflammatory conditions.
At a glance
| Generic name | phosphate and betamethasone acetate, 2 mL. |
|---|---|
| Also known as | cronodose |
| Sponsor | Hospital Italiano de Buenos Aires |
| Drug class | Corticosteroid (glucocorticoid) |
| Target | Glucocorticoid receptor (GR) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Rheumatology / Dermatology |
| Phase | FDA-approved |
Mechanism of action
Betamethasone acetate is a synthetic glucocorticoid that enters cells and binds to intracellular glucocorticoid receptors, translocating to the nucleus to modulate gene expression. This results in decreased production of inflammatory mediators (cytokines, chemokines, adhesion molecules) and suppression of immune cell activation and migration. The phosphate salt formulation enhances solubility and allows for parenteral administration, typically as an intra-articular or soft-tissue injection.
Approved indications
- Intra-articular injection for inflammatory arthritis and joint inflammation
- Soft-tissue injection for bursitis, tendinitis, and localized inflammatory conditions
- Dermatologic inflammatory conditions
Common side effects
- Local injection site reactions (pain, swelling, erythema)
- Transient hyperglycemia
- Systemic corticosteroid effects with repeated or high-dose use (HPA axis suppression, immunosuppression)
- Infection risk at injection site
Key clinical trials
- Efficacy of Corticosteroid Injection and Nerve Hydrodissection in Carpal Tunnel Syndrome (NA)
- Low Dose Antenatal Corticosteroids for Late Preterm Delivery (NA)
- Local Betamethasone Versus Triamcinolone Injection in Management of Thyroid Eye Disease (PHASE2, PHASE3)
- Antenatal Late Preterm Steroids (ALPS): A Randomized Placebo-Controlled Trial (PHASE3)
- Effect of ZILRETTA Versus CELESTONE on Quality of Life, Pain, Neuromuscular Function, and Physical Performance (PHASE4)
- A Comparative Effectiveness Randomised Placebo Controlled Pilot Trial of the Management of Acute Lumbar Radicular Pain (PHASE2)
- ORTHOVISC Shoulder Osteoarthritis Study (PHASE3)
- Steroids in the Postoperative Transient Hypoparathyroidism Total Thyroidectomy (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: